The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
IFN-λs
Open accessAbstract
For decades, type I IFNs have been considered indispensable and unique antiviral mediators for the activation of rapid innate antiviral protection. However, the recent discovery of type III IFNs is challenging this paradigm. Since their identification in 2002/2003 by two independent groups, type III IFNs or IFN-λs, also known as IL-28/29, have been the subject of increased study with consequent recognition of their importance in virology and immunology. Initial reports suggested that IFN-λs functionally resemble type I IFNs. Although IFN-λs and classical type I IFNs (IFN-α/β) utilize distinct receptor complexes for signaling, both types of IFNs activate similar intracellular signaling pathways and biological activities, including the ability to induce antiviral state in cells, and both type I and type III IFNs are induced by viral infection. However, different antiviral potency, pattern of their induction and differential tissue expression of their corresponding receptor subunits suggest that the type I and type III IFN antiviral systems do not merely duplicate each other. Recent studies have started to reveal unique biological activities of IFN-λs in and beyond innate antiviral immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of deficient type III interferon-λ production in asthma exacerbations
Contoli, M., Message, S. D., Laza-Stanca, V., Edwards, M. R., Wark, P. A. B., Bartlett, N. W., Kebadze, T., Mallia, P., Stanciu, L. A., Parker, H. L., et al. (2006) · Nature Medicine · doi:10.1038/nm1462 · Cited by 1,006
Self-citationWathelet, M. G., Lin, C. H., Parekh, B. S., Ronco, L. V., Howley, P. M., & Maniatis, T. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80051-9 · Cited by 730
Cited by
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,072
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
Lazear, H. M., Nice, T. J., & Diamond, M. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.001 · Cited by 480
Sato, S., Li, K., Kameyama, T., Hayashi, T., Ishida, Y., Murakami, S., Watanabe, T., Iijima, S., Sakurai, Y., Watashi, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2014.12.016 · Cited by 413
Diverse intracellular pathogens activate type III interferon expression from peroxisomes
Odendall, C., Dixit, E., Stavru, F., Bierne, H., Franz, K. M., Durbin, A. F., Boulant, S., Gehrke, L., Cossart, P., & Kagan, J. C. (2014) · Nature Immunology · doi:10.1038/ni.2915 · Cited by 374
Guarding the frontiers: the biology of type III interferons
Wack, A., Terczyńska-Dyla, E., & Hartmann, R. (2015) · Nature Immunology · doi:10.1038/ni.3212 · Cited by 364
Hernández, P. P., Mahlakõiv, T., Yang, I., Schwierzeck, V., Nguyen, N., Guendel, F., Gronke, K., Ryffel, B., Hölscher, C., Dumoutier, L., et al. (2015) · Nature Immunology · doi:10.1038/ni.3180 · Cited by 287
The role of cytokines in inflammatory bone loss
Souza, P. P. C., & Lerner, U. H. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.822766 · Cited by 269
Interferons and Their Stimulated Genes in the Tumor Microenvironment
Cheon, H., Borden, E. C., & Stark, G. R. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.02.002 · Cited by 255
Interfering with immunity: detrimental role of type I IFNs during infection
Stifter, S. A., & Feng, C. G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402794 · Cited by 78
Metadata
- Authors
- Kotenko, S. V.
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 23
- Issue
- 5
- Pages
- 583-590
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W4233800959
- Cited by
- 193
- References
- 2
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.